99 related articles for article (PubMed ID: 8471596)
21. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.
Kruse CA; Mitchell DH; Kleinschmidt-DeMasters BK; Bellgrau D; Eule JM; Parra JR; Kong Q; Lillehei KO
J Neurooncol; 1993 Feb; 15(2):97-112. PubMed ID: 8509824
[TBL] [Abstract][Full Text] [Related]
22. Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones.
Bookman MA; Swerdlow R; Matis LA
J Immunol; 1987 Nov; 139(9):3166-70. PubMed ID: 2822805
[TBL] [Abstract][Full Text] [Related]
23. A multiple modality approach combining the effect of conditioning with adoptive chemoimmunotherapy.
Ghanta VK; Hiramoto NS; Soong SJ; Miller DM; Hiramoto RN
Int J Neurosci; 1993; 71(1-4):251-65. PubMed ID: 8407150
[TBL] [Abstract][Full Text] [Related]
24. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study.
Graham S; Babayan RK; Lamm DL; Sawczuk I; Ross SD; Lavin PT; Osband ME; Krane RJ
Semin Urol; 1993 Feb; 11(1):27-34. PubMed ID: 8465126
[No Abstract] [Full Text] [Related]
25. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan.
Wise JA; Mokyr MB; Dray S
Cancer Res; 1989 Jul; 49(13):3613-9. PubMed ID: 2567207
[TBL] [Abstract][Full Text] [Related]
28. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.
Osband ME; Lavin PT; Babayan RK; Graham S; Lamm DL; Parker B; Sawczuk I; Ross S; Krane RJ
Lancet; 1990 Apr; 335(8696):994-8. PubMed ID: 1970108
[TBL] [Abstract][Full Text] [Related]
29. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
30. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection.
Mie K; Shimada T; Akiyoshi H; Hayashi A; Ohashi F
Vet Immunol Immunopathol; 2016 Sep; 177():58-63. PubMed ID: 27436446
[TBL] [Abstract][Full Text] [Related]
31. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
32. [Biotherapy of advanced cancer by infusion of in vitro activated autolymphocytes].
Du X; Zhang M; Zhao M
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):464-6. PubMed ID: 8698005
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
[TBL] [Abstract][Full Text] [Related]
34. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
[TBL] [Abstract][Full Text] [Related]
35. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
Wang X; Ren J; Zhang J; Yan Y; Jiang N; Yu J; Di L; Song G; Che L; Jia J; Zhou X; Yang H; Lyerly HK
Clin Transl Oncol; 2016 Jan; 18(1):82-7. PubMed ID: 26266766
[TBL] [Abstract][Full Text] [Related]
37. Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study).
Yoshida Y; Naito M; Yamada T; Aisu N; Kojima D; Mera T; Tanaka T; Naito K; Yasumoto K; Kamigaki T; Gotoh S; Kodama S; Yamashita Y; Hasegawa S
Anticancer Res; 2017 Jul; 37(7):3941-3946. PubMed ID: 28668898
[TBL] [Abstract][Full Text] [Related]
38. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
[TBL] [Abstract][Full Text] [Related]
39. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
40. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
